Biotechnology Startup Funding 2025-2026

What are all the funding deals in the biotechnology market from August 2025 to September 2026?

The table below lists the clean, exact-value equity financings identified in the verified biotechnology dataset between August 2025 and September 2, 2026. We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes, including biopharma R&D and therapeutics, molecular diagnostics, and core life-science research tools and reagents.

The dataset excludes routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture or industrial bioapplications unless explicitly in scope. Because the systematic source base is strongest for large financings, this table should be read as a verified large-round dataset rather than an exhaustive global census down to $300K. For a wider view of the industry, see our Biotechnology market report.

How active has fundraising been in the biotechnology market?

As of September 2026, fundraising in the biotechnology market has been extremely active at the large-round end over the 12-month analytical period. The clean verified sample contains 77 exact financings totaling approximately $11.75B, raised by 75 unique biotechnology companies.

That total should be interpreted as a floor rather than the total market. The strongest systematic source used in the research is optimized toward financings above $50M, leaving much of the $300K-to-$50M biotechnology market outside systematic coverage.

The scale of visible financing is nevertheless substantial. The verified sample has an average financing size of approximately $153M and a median of $101M, showing how strongly large institutional rounds dominate the observable dataset.

Industry-wide monthly sources confirm that the missing tail matters. January 2026 alone contained 31 significant private biotechnology financings according to a broader industry review, showing that the 77-row clean table cannot represent every qualifying transaction globally.

For a deeper view of financing activity, companies and market structure, see our full biotechnology market report.

How concentrated has fundraising been in the biotechnology market?

As of September 2026, fundraising in the biotechnology market is meaningfully concentrated, but the 12-month verified sample is not completely dependent on one company. The largest financing represents 17.9% of captured capital, while the top 3 rounds represent 26.7% and the top 5 represent 32.6%.

Isomorphic Labs is the largest outlier at $2.1B. Kailera Therapeutics follows at $600M, NewLimit at $435M, Tubulis at $361M and Ollin Biosciences at $330M.

The top 10 financings collectively account for approximately 44.3% of the $11.75B clean sample. This means more than half of captured capital still sits outside the ten largest rounds, despite the presence of a $2.1B outlier.

Concentration therefore matters most when interpreting short-term category or regional totals. One financing can materially alter an apparent trend even when the broader biotechnology funding base remains diversified across many companies.

How much of the biotechnology funding signal is driven by outliers?

As of September 2026, outliers materially influence the biotechnology funding signal over the 12-month analytical period. Isomorphic Labs alone contributes $2.1B, equivalent to 17.9% of all capital in the 77-deal clean sample.

The effect is particularly important for Europe and Therapeutics Discovery Platforms because Isomorphic Labs belongs to both. Any capital-share analysis of either group should therefore be shown both with and without the $2.1B financing.

Several additional financings are individually capable of moving aggregate statistics: Kailera raised $600M, NewLimit $435M, Tubulis $361M, Ollin Biosciences $330M and Kriya Therapeutics $313M.

The practical reading rule is simple: biotechnology dollar totals should always be checked against their top contributors. We examine those concentration effects in more detail in our biotechnology funding analysis.

Is the biotechnology market broad with many targets, or narrow with few fundable companies?

As of September 2026, the biotechnology market itself is broad, but the 12-month verified large-round sample is narrow in what it captures. The clean dataset contains 75 unique companies, yet 69 of its 77 financings are classified as Therapeutics Discovery Platforms.

That concentration does not mean biotechnology lacks diagnostics, synthetic biology or bioprocessing companies. It means the systematic source base is more likely to capture therapeutics companies because their financing requirements frequently exceed $50M.

Only two companies appear twice in the clean exact-value sample: Crystalys Therapeutics and Ollin Biosciences. Most companies therefore contribute one observed financing even though the market contains a large number of separate institutional targets.

The correct conclusion is that the large-round opportunity set is broad by company count but narrow by business model. A full $300K+ census would almost certainly broaden the category mix substantially.

Is biotechnology mostly an early-stage formation market or a late-stage scaling market?

As of September 2026, the biotechnology market cannot be described cleanly as either early-stage formation or late-stage scaling based on financing labels alone. Over the 12-month sample, Series B contributes the most capital at approximately $5.51B, while Series A still represents 23 financings and $2.40B.

Series C contributes 12 financings and approximately $1.82B, while Series D+ contributes five financings and $706M. Nine financings totaling about $1.18B have an Unknown stage.

The important complication is that biotechnology financing stage often diverges from scientific maturity. Crystalys raised a $205M Series A around an asset already approved in Asia, while Expedition and other large Series A companies were built around advanced or externally sourced programs.

Corporate financing stage should therefore be analyzed separately from preclinical, Phase 1, Phase 2 or registration-stage asset maturity. For more on this distinction, see our report on biotechnology companies and financing stages.

Which categories attract the most investor attention in biotechnology?

As of September 2026, Therapeutics Discovery Platforms attract by far the most investor attention in the 12-month verified biotechnology sample. They account for 69 of 77 clean financings and approximately $10.69B of the $11.75B captured.

Gene Editing Companies account for four clean financings totaling $650M, led by Kriya Therapeutics at $313M. Cell Therapy Developers also account for four financings, totaling $412M.

Diagnostic Technology Firms, Synthetic Biology Platforms and Bioprocessing Tool Providers do not appear in the clean large-round sample. That absence should not be interpreted as no funding activity because smaller typical check sizes are precisely what a $50M-heavy source base is least likely to capture.

The category ranking is therefore useful for understanding where very large institutional checks are going, but not for measuring the full formation rate of biotechnology companies.

Which categories attract disproportionately large checks in the biotechnology market?

As of September 2026, Therapeutics Discovery Platforms attract the largest checks in absolute terms across the 12-month verified biotechnology sample. Their 69 clean financings total approximately $10.69B, or more than 90% of captured capital.

The category includes several fundamentally different financing architectures: AI-native discovery at Isomorphic Labs, metabolic medicines at Kailera, epigenetic reprogramming at NewLimit, ADC technology at Tubulis and clinical-stage ophthalmology at Ollin.

Gene Editing Companies have fewer observations but still attract large institutional rounds. Four clean deals total $650M, including Kriya at $313M, AAVantgarde Bio at $141M, Profluent at $106M and Epicrispr at $90M.

Cell Therapy Developers show a more selective financing profile, with four clean transactions totaling $412M. The strongest rounds generally combine modality differentiation with clinical evidence, manufacturing progress or a clearer deployment path.

Which geographies matter most for fundraising in the biotechnology market?

As of September 2026, North America matters most for biotechnology fundraising in the 12-month verified sample. The region contributes 58 of 77 clean financings and approximately $7.44B of the $11.75B captured.

Europe contributes 14 clean financings totaling approximately $3.72B. That dollar share is heavily influenced by Isomorphic Labs' $2.1B Series B, so Europe's observed capital weight is much larger than its deal-count share.

Asia-Pacific contributes five clean financings and approximately $593M. Minghui Pharmaceutical, Arnatar Therapeutics, Corxel Pharmaceuticals, QL Biopharm and Accro Bioscience make up the exact-value Asia-Pacific sample.

The large-round evidence therefore supports clear North American leadership but not an exact global deal-formation share. For a broader geographic view, explore our biotechnology market report by region.

Is the biotechnology opportunity set broad or concentrated in one hub?

As of September 2026, the biotechnology opportunity set is geographically concentrated in North America at the large-round level, but it is not a one-hub market. Over the 12-month sample, North America accounts for 58 deals, Europe for 14 and Asia-Pacific for five.

Europe demonstrates that lower deal density does not prevent very large individual financings. Isomorphic Labs raised $2.1B, Tubulis $361M, Hemab Therapeutics $157M and Vaderis Therapeutics $152M.

Asia-Pacific is more lightly represented in this large-round sample, yet Corxel raised $287M and Minghui raised $131M. Those transactions show that global institutional capital remains available for differentiated programs with advanced or globally relevant assets.

No clean exact-value deal in the supplied sample is classified in Latin America, the Middle East or Africa. Given the data-coverage limitation, that should be read as absence from this verified large-round dataset rather than proof of zero biotechnology financing.

Is biotechnology a market of small experiments or scaled financings?

As of September 2026, the visible biotechnology dataset is overwhelmingly a market of scaled financings over the 12-month analytical period. The median clean round is $101M and the average is approximately $153M.

Ten of the 77 clean financings are $200M or larger. Another 32 fall from $100M to below $200M, while 35 fall from $50M to below $100M.

There are no clean transactions below $50M in this particular statistical sample. That is a data-coverage effect rather than evidence that small biotechnology rounds disappeared, because the principal systematic tracker explicitly concentrates on large financings.

This makes the sample excellent for studying institutional capital concentration but unsuitable for estimating the real median biotechnology round. A deeper discussion of financing scale is available in our full biotechnology market deck.

Who are the investors that appear the most in biotechnology fundraising?

As of September 2026, specialist life-science investors dominate repeat participation in the biotechnology market over the 12-month analytical period. RA Capital, OrbiMed, Sofinnova, Novo Holdings, Janus Henderson, Alexandria Venture Investments, Forbion and several other institutional investors recur across multiple financings.

RA Capital appears across metabolic disease, ophthalmology, antibodies, genetic medicine and immunology. OrbiMed similarly spans multiple therapeutic areas rather than representing a concentrated bet on one modality.

Strategic pharmaceutical investors also recur repeatedly. Eli Lilly, Sanofi, Pfizer, Regeneron, Bristol Myers Squibb and other industry participants invest upstream alongside specialist financial investors, effectively using venture syndicates as external portfolio-option mechanisms.

Syndicate composition can therefore add information beyond round size. Multiple credible specialists or competing pharmaceutical companies in the same financing may offer stronger external validation than a large amount supplied by a narrow sponsor base.

Individual investor check sizes are rarely disclosed, so participation frequency is more reliable than assigning each investor the full value of every round it joined. Round size measures company financing, not the amount contributed by each named investor.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.